Moderna cuts its sales forecast for 2025 due to the slow start of the VRS vaccine and weak demand for the COVID vaccine

Moderne cut its sales forecast for 2025 to 1,000 million dollars on Monday, hurt by the slow release of its vaccine against the respiratory syncytial virus (RSV) and the weak demand for the COVID-19 vaccine.

Prevé unos ingresos anuales de entre 1,500 y 2,500 milliones de dolares, principalamente en el segundo semestre, una cifra inferior a su previsión anterior de entre 2,500 y 3,500 milliones de dolares del merca 200 m. de dollars, see data from LSEG.

Moderna has been struggling to pass its COVID vaccine to its most recent vaccine against the VRS, because its adoption has been slower than expected, which has forced the company to cut costs.

El fabricante de vacunas pretended to reduce costs en efectivo in 2025 and 1,000 million dollars, con un plan de 500 milliones adicionales en 2026, sigún declarado el consejero delegado Stéphane Bancel.

I hope to finish 2025 with an effective and unas investments of unos 6,000 millones de dolares.

The company is also betting on new products to help accelerate growth. Has presented a request before the FDA estadounidense para la approvación de su vacuna combinada para proteger contra el COVID-19 y la gripe.

The regulatory body also plans to make a decision before May on the request for its new generation COVID-19 vaccine, according to Moderna.

The manufacturer of vaccines hopes to communicate the data of a trial of their vaccine against the seasonal flu this year, if they accumulate enough cases in the first season. On the contrary, the studio will continue for a second season, said Moderna.

Informará de los results del cuarto trimestre el 14 febrero.